Systemic autoimmune diseases (SAID) are a heterogeneous group of diseases with a common etiopathogenic basis, often requiring immunosuppressive therapies (DMARD) [1]. Although case-control studies reported no significant differences in coronavirus disease 2019 (COVID-19) outcomes, large population-based studies analyzing baseline risk factors reported a 2–3 times higher rate of poor outcomes in patients with SAID [1].
